Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-24T13:29:15.908Z Has data issue: false hasContentIssue false

30 - From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?

from Section 3 - Alzheimer’s Disease Clinical Trials

Published online by Cambridge University Press:  03 March 2022

By
Soeren Mattke
Edited by
Jeffrey Cummings ,
Jefferson Kinney  and
Howard Fillit
Jeffrey Cummings
Affiliation:
University of Nevada, Las Vegas
Jefferson Kinney
Affiliation:
University of Nevada, Las Vegas
Howard Fillit
Affiliation:
Alzheimer’s Drug Discovery Foundation
Get access

Summary

The chapter explores whether high-income countries are ready for the first disease-modifying Alzheimer’s disease (AD) treatment, approved in the USA in February 2021. It looks at the capacity to provide diagnostic services relative to the expected demand, institutional preparedness, and potential solutions to overcome capacity constraints. Wait times are projected to differ substantially. Initial average wait times range from 5 months in Germany to 28 months in Canada. In France, Canada, and Taiwan, we project it will take over a decade to clear the backlog of prevalent cases and to make a treatment accessible with little delay, because of scarcity of dementia specialists, and aggravated by the lack of financial and structural plannin. Potential solutions include broadening the dementia workforce by integration of primary care clinicians and other specialists, care models that leverage specialist time, and telecare-supported models. Better diagnostic technology to detect cognitive decline and the AD pathology in primary care settings and predictive models to triage patients show potential to improve access.

Keywords

Alzheimer’s diseasedisease-modifying treatmentpreparednessinfrastructurememory carecomparative studydementia
Type
Chapter
Information
Alzheimer's Disease Drug Development
Research and Development Ecosystem
 , pp. 343 - 353
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Jack, CR, Bennett, DA, Blennow, K, et al. NIA–AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14: 535–62.CrossRefGoogle Scholar
Petersen, RC, Lopez, O, Armstrong, MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation subcommittee of the American Academy of Neurology. Neurology 2018; 90: 126–35.CrossRefGoogle Scholar
Liu, JL, Hlávka, JP, Hillestad, R, Mattke, S. Assessing the Preparedness of the U.S. health care system infrastructure for an Alzheimer’s treatment. Available at: www.rand.org/pubs/research_reports/RR2272.html (accessed July 9, 2021).Google Scholar
Hlavka, JP, Mattke, S, Liu, JL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer’s treatment. Rand Health Q 2019; 8: 2.Google ScholarPubMed
Hebert, LE, Weuve, J, Scherr, PA, Evans, DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 2013; 80: 1778–83.CrossRefGoogle ScholarPubMed
Sado, M, Ninomiya, A, Shikimoto, R, et al. The estimated cost of dementia in Japan, the most aged society in the world. PLoS One 2018; 13: e0206508.Google Scholar
Lang, L, Clifford, A, Wei, L, et al. Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis. BMJ Open 2017; 7: e011146.CrossRefGoogle ScholarPubMed
Sperling, RA, Rentz, DM, Johnson, KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014; 6: 228fs13.Google Scholar
Baxi, SM, Girosi, F, Liu, JL. Assessing the preparedness of the Australian health care system infrastructure for an Alzheimer’s disease-modifying therapy. Available at: www.rand.org/pubs/research_reports/RR2891.html (accessed July 9, 2021).Google Scholar
Liu, JL, Hlavka, JP, Coulter, DT, et al. Assessing the preparedness of the Canadian health care system infrastructure for an Alzheimer’s treatment. Available at: www.rand.org/pubs/research_reports/RR2744.html (accessed July 9, 2021).Google Scholar
Mattke, HJ, Yoong, J, Wang, M, Goto, R. Assessing the preparedness of the Japanese health care system infrastructure for an Alzheimer’s treatment. Available at: https://cesr.usc.edu/sites/default/files/CESR%202019-101.pdf (accessed July 9, 2021) .Google Scholar
Hankyung Jun, SKC, Yoong, J, Mattke, S. Assessing the preparedness of the Korean healthcare system infrastructure for an Alzheimer’s treatment. Available at: https://cesr.usc.edu/sites/default/files/Korea_Infrastructure_Projection_final.pdf (accessed July 9, 2021) .Google Scholar
Hankyung Jun, SKC, Yoong, J, Mattke, S. Assessing the preparedness of the Taiwanese healthcare system infrastructure for an Alzheimer’s treatment. Available at: https://cesr.usc.edu/sites/default/files/Taiwan_Infrastructure_Projection_final.pdf (accessed July 9, 2021).Google Scholar
Ritchie, CW, Russ, TC, Banerjee, S, et al. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease. Alzheimers Res Ther 2017; 9: 85.Google Scholar
Martínez-Lagea, P, Martín-Carrascob, M, Arrietad, E, Rodrigof, J, Formigac, F. Map of Alzheimer’s disease and other dementias in Spain. MapEA Project. Rev Esp Geriatr Gerontol 2018; 53: 26–37.Google Scholar
Jun, H, Cho, SK, Aliyev, ER, Mattke, S, Suen, S-C. How much value would a treatment for Alzheimer’s disease offer? Cost-effectiveness thresholds for pricing a disease-modifying therapy. Curr Alzheimer Res 2020; 17 : 819–22.Google ScholarPubMed
Mattke, S, Cho, SK, Bittner, T, Hlavka, J, Hanson, M. Blood-based biomarkers for Alzheimer’s pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times. Alzheimers Dement (Amst) 2020; 12: e12081.Google ScholarPubMed
Ngandu, T, Lehtisalo, J, Solomon, A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 385: 2255–63.CrossRefGoogle Scholar
Rabinovici, GD, Gatsonis, C, Apgar, C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019; 321: 1286–94.CrossRefGoogle ScholarPubMed
Russell-Babin, K, Wurmser, T. Transforming care through top-of-license practice. Nurs Manage 2016; 47: 24–8.CrossRefGoogle Scholar
Mattke, S, Hoch, E. Borrowing for the cure. Available at: www.rand.org/pubs/perspectives/PE141.html (accessed July 9, 2021).Google Scholar
Lam, J, Jun, H, Cho, S K, Hanson, M, Mattke, S. Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer’s disease treatment. Alzheimers Dement (Amst) 2021; 13: e12159.Google Scholar
Greaves, I, Greaves, N, Walker, E, et al. Gnosall Primary Care Memory Clinic: eldercare facilitator role description and development. Dementia (London) 2015; 14: 389–408.CrossRefGoogle ScholarPubMed
Engedal, K, Gausdal, M, Gjora, L, Haugen, PK. Assessment of dementia by a primary health care dementia team cooperating with the family doctor: the Norwegian model. Dement Geriatr Cogn Disord 2012; 34: 263–70.Google Scholar
Lee, L, Hillier, LM, Heckman, G, et al. Primary care-based memory clinics: expanding capacity for dementia care. Can J Aging 2014; 33: 307–19.CrossRefGoogle ScholarPubMed
Alzheimer’s Association. The Alzheimer’s and Dementia Care ECHO® Program. Available at: www.alz.org/professionals/professional-providers/echo-alzheimers-dementia-care-program (accessed June 6, 2019).Google Scholar
Lam, J, Hlávka, J, Mattke, S. The potential emergence of disease-modifying treatments for Alzheimer disease: the role of primary care in managing the patient journey. J Am Board Fam Med 2019; 32: 931–40.CrossRefGoogle ScholarPubMed
Palmqvist, S, Janelidze, S, Stomrud, E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol 2019; 76: 1060–9.CrossRefGoogle ScholarPubMed
Palmqvist, S, Janelidze, S, Quiroz, YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020; 324: 772.CrossRefGoogle ScholarPubMed
Kourtis, LC, Regele, OB, Wright, JM, Jones, GB. Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity. NPJ Digit Med 2019; 2: 9.Google Scholar
Buegler, M, Harms, RL, Balasa, M, et al. Digital biomarker-based individualized prognosis for people at risk of dementia. Alzheimers Dement (Amst) 2020; 12: e12073.Google Scholar
Biogen. Biogen to launch pioneering study to develop digital biomarkers of cognitive health using apple watch and iphone [press release]. Available at: https://investors.biogen.com/news-releases/news-release-details/biogen-launch-pioneering-study-develop-digital-biomarkers (accessed January 2021).Google Scholar
Arnett, DK, Blumenthal, RS, Albert, MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol 2019; 74: e177–232.Google Scholar
Progetto Interceptor. Interceptor: the project. Available at: www.interceptorproject.com/en/lo-studio-interceptor/ (accessed July 9, 2021).Google Scholar
Belleville, S, Leblanc, AC, Kergoat, M-J, et al. The Consortium for the early identification of Alzheimer’s disease – Quebec (CIMA-Q). Alzheimers Dement (Amst) 2019; 11: 787–96.Google Scholar
Janelidze, S, Mattsson, N, Palmqvist, S, et al. Plasma p-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med 2020; 26: 379–86.Google Scholar
Mattke, S, Klautzer, L, Mengistu, T. Medicines as a service. Available at: www.rand.org/pubs/occasional_papers/OP381.html (accessed July 9, 2021).Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×